Home > Research > Publications & Outputs > Open letter to UK Prime Minister David Cameron ...
View graph of relations

Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. / Archibald, Kathy; Coleman, Robert; Foster, Christopher et al.
In: Lancet, Vol. 377, No. 9781, 04.06.2011, p. 1915.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Archibald K, Coleman R, Foster C, Wright K. Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. Lancet. 2011 Jun 4;377(9781):1915. doi: 10.1016/S0140-6736(11)60802-7

Author

Archibald, Kathy ; Coleman, Robert ; Foster, Christopher et al. / Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. In: Lancet. 2011 ; Vol. 377, No. 9781. pp. 1915.

Bibtex

@article{b2f39d4ca4bb42158a4524325c8854df,
title = "Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines",
keywords = "Animal Experimentation, Animals, Clinical Trials as Topic, Drug Approval, Drug Costs, Drug Industry, Drug-Related Side Effects and Adverse Reactions, Great Britain, Humans",
author = "Kathy Archibald and Robert Coleman and Christopher Foster and Karen Wright",
year = "2011",
month = jun,
day = "4",
doi = "10.1016/S0140-6736(11)60802-7",
language = "English",
volume = "377",
pages = "1915",
journal = "Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9781",

}

RIS

TY - JOUR

T1 - Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines

AU - Archibald, Kathy

AU - Coleman, Robert

AU - Foster, Christopher

AU - Wright, Karen

PY - 2011/6/4

Y1 - 2011/6/4

KW - Animal Experimentation

KW - Animals

KW - Clinical Trials as Topic

KW - Drug Approval

KW - Drug Costs

KW - Drug Industry

KW - Drug-Related Side Effects and Adverse Reactions

KW - Great Britain

KW - Humans

U2 - 10.1016/S0140-6736(11)60802-7

DO - 10.1016/S0140-6736(11)60802-7

M3 - Journal article

C2 - 21641471

VL - 377

SP - 1915

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9781

ER -